Trial Profile
Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms XELAVIRI
- 01 Jul 2023 Results presented at the 25th World Congress on Gastrointestinal Cancer
- 05 Aug 2022 Results published in the European Journal of Cancer
- 07 Jun 2022 Results of pooled analysis assessing prognostic and predictive value of primary tumor location by using data from five studies (FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI) presented at the 58th Annual Meeting of the American Society of Clinical Oncology